Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rupining is a Traditional Chinese Medicine (TCM) formulation developed by Wuhan Pharmaceutical Valley Technology Development Co., Ltd., specifically indicated for the treatment of breast hyperplasia (lobular hyperplasia) and associated breast pain. The medication is typically formulated as tablets and contains a complex blend of herbal extracts, including *Sparganium stoloniferum*, *Curcuma zedoaria*, and *Prunella vulgaris*. Its mechanism of action involves "softening hardness and dissipating nodules" and "soothing the liver and regulating qi" according to TCM principles. Pharmacologically, it is thought to modulate the endocrine environment, particularly by balancing estrogen and progesterone levels, and providing anti-inflammatory and analgesic effects to reduce mammary gland congestion and hyperplasia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rupining.